Caribou Biosciences, Inc.
CRBUNASDAQHealthcare● Active
$1.86
$-0.06(-2.89%)
Market Cap$184932100
P/E Ratio—
52W High$3.535
52W Low$1.04
Caribou Biosciences, Inc. (CRBU) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRBU · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.26
Est. -$0.33 · +21.2%
Revenue
$0.00B
Est. $0.00B · +8.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 8-Quarter EPS Beat Streak
CRBU reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.33 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.33 | -$0.26 | +21.2% | $0.00B | $0.00B | +8.3% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.33 | -$0.28 | +15.2% | $0.00B | $0.00B | +78.6% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.36 | -$0.30 | +16.7% | $0.00B | $0.00B | +12.3% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.40 | -$0.35 | +12.5% | $0.00B | $0.00B | +74.1% |
| — Q2 FY2025 | May 8, 2025 | -$0.43 | -$0.43 | +0.0% | $0.00B | $0.00B | +27.1% |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$0.40 | -$0.39 | +2.5% | $0.00B | $0.00B | -1.4% |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.44 | -$0.38 | +13.6% | $0.00B | $0.00B | -34.2% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.33
EPS Surpr.
+21.2%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.28
EPS Est.
-$0.33
EPS Surpr.
+15.2%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.36
EPS Surpr.
+16.7%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.35
EPS Est.
-$0.40
EPS Surpr.
+12.5%
Revenue
$0.00B
Q2 FY2025
May 8, 2025
EPS Actual
-$0.43
EPS Est.
-$0.43
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.40
EPS Surpr.
+2.5%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.38
EPS Est.
-$0.44
EPS Surpr.
+13.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2026 | $-0.41 | $-0.34 | $-0.27 | 2 |
| Q2 FY2026 | $-0.36 | $-0.31 | $-0.27 | 2 |
| Q1 FY2026 | $-0.39 | $-0.31 | $-0.27 | 2 |
| Q4 FY2025 | $-0.33 | $-0.31 | $-0.28 | 6 |
| Q3 FY2025 | $-0.39 | $-0.35 | $-0.29 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +21.2% | $1.95 | $1.88 | -3.59% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +15.2% | $1.80 | $1.71 | -5.00% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +16.7% | $2.24 | $2.26 | +0.89% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +12.5% | $1.71 | $1.79 | +4.68% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $0.76 | $0.79 | +3.95% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +2.5% | $1.16 | $1.11 | -4.31% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +13.6% | $2.56 | $2.75 | +7.42% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +6.7% | $1.96 | $1.96 | +0.00% |
Q2 FY2026-3.59%
Report Date
May 7, 2026
EPS Beat/Miss
+21.2%
Price Before
$1.95
Price After
$1.88
Q1 FY2026-5.00%
Report Date
Mar 5, 2026
EPS Beat/Miss
+15.2%
Price Before
$1.80
Price After
$1.71
Q4 FY2025+0.89%
Report Date
Nov 12, 2025
EPS Beat/Miss
+16.7%
Price Before
$2.24
Price After
$2.26
Q3 FY2025+4.68%
Report Date
Aug 12, 2025
EPS Beat/Miss
+12.5%
Price Before
$1.71
Price After
$1.79
Q2 FY2025+3.95%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.76
Price After
$0.79
Q1 FY2025-4.31%
Report Date
Mar 10, 2025
EPS Beat/Miss
+2.5%
Price Before
$1.16
Price After
$1.11
Q4 FY2024+7.42%
Report Date
Nov 6, 2024
EPS Beat/Miss
+13.6%
Price Before
$2.56
Price After
$2.75
Q3 FY2024+0.00%
Report Date
Aug 6, 2024
EPS Beat/Miss
+6.7%
Price Before
$1.96
Price After
$1.96
Avg Beat Reaction+0.51%
Beat Rate8 / 8 quarters
Largest Move+7.42% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRBU ends December
Caribou Biosciences, Inc. (CRBU) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.33 by +21.2%. CRBU has beaten EPS estimates for 8 consecutive quarters. The next CRBU earnings date is expected around September 1, 2026.
Each quarter, investors track CRBU earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRBU revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRBU's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRBU earnings · 5 questionsCaribou Biosciences, Inc.'s next earnings report is expected around September 1, 2026. CRBU typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRBU historically reports after market close (AMC).
CRBU earnings datewhen is CRBU earningsCRBU next earnings datewhen does CRBU report earningsCRBU earnings calendar
▸ Source: FMP · Caribou Biosciences, Inc. SEC filings · US GAAP · Caribou Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026